TIHAMER ORBAN, M.D.
Medical Practice in Boston, MA
License number
Massachusetts 154893
Category
Medical Practice
Type
Pediatric Endocrinology
Address
Address
2
Joslin Diabetes Center One Joslin Pl, Boston, MA 02215
64 Aspinwall Ave, Brookline, MA 02446
64 Aspinwall Ave, Brookline, MA 02446
Phone
(617) 713-3442
Organization information
See more information about TIHAMER ORBAN at bizstanding.comTihamer Orban MD
1 Joslin Pl, Boston, MA 02215
Industry:
Pediatric Endocrinologist, Pediatrician
Phone:
(617) 713-3442 (Phone)
Tihamer Orban
Professional information
Tihamer Orban, Boston MA
Specialties:
Internal Medicine, Endocrinology, Diabetes & Metabolism, Pediatrics, Pediatric Clinical & Laboratory Immunology, Pediatric Endocrinology
Work:
Joslin Diabetes Center
1 Joslin Pl, Boston, MA 02215
1 Joslin Pl, Boston, MA 02215
Education:
Albert Szent-Gyorgy University (1975)
Researcher At Joslin Diabetes Center
Position:
Researcher at Joslin Diabetes Center
Location:
Greater Boston Area
Industry:
Hospital & Health Care
Work:
Joslin Diabetes Center
-
Researcher
Dr. Tihamer Orban, Boston MA - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
JOSLIN DIABETES CENTER
1 Joslin Pl, Boston 02215
(617) 732-2675 (Phone), (617) 732-2452 (Fax)
1 Joslin Pl, Boston 02215
(617) 732-2675 (Phone), (617) 732-2452 (Fax)
Languages:
English
Education:
Medical School
University of Szeged Faculty of Medicine
Szent Gyorgyi Albert Uhungary
Children's Hospital Hungary
Joslin Diabetes Center/Harvard
Semmelweis University Hungary
University of Szeged Faculty of Medicine
Szent Gyorgyi Albert Uhungary
Children's Hospital Hungary
Joslin Diabetes Center/Harvard
Semmelweis University Hungary
Tihamer Orban
Location:
Greater Boston Area
Industry:
Hospital & Health Care
Tihamer Orban, Boston MA
Specialties:
Pediatrician
Address:
1 Joslin Pl, Boston, MA 02215
Methods For Treating Autoimmune Disease By Inducing Autoantigen-Specific Regulatory Cd4+ T Cells
US Patent:
2009014, Jun 4, 2009
Filed:
Oct 27, 2008
Appl. No.:
12/290049
Inventors:
Tihamer Orban - Brookline MA, US
Peter Blackburn - New York NY, US
Peter Blackburn - New York NY, US
Assignee:
Joslin Diabetes Center, Inc. - Boston MA
Mercia Pharma, Inc. - Scarsdale NY
Mercia Pharma, Inc. - Scarsdale NY
International Classification:
A61K 45/00, A61P 3/10
US Classification:
424 937
Abstract:
Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.
Combinations Of Modalities For The Treatment Of Diabetes
US Patent:
2013031, Nov 28, 2013
Filed:
Jun 27, 2012
Appl. No.:
13/534571
Inventors:
Tihamer Orban - Brookline MA, US
Assignee:
ORBAN BIOTECH LLC - Brookline MA
International Classification:
A61K 39/395, A61P 3/10
US Classification:
4241341
Abstract:
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.
Autoantigen Composition
US Patent:
2003004, Mar 6, 2003
Filed:
Jan 4, 2002
Appl. No.:
10/038686
Inventors:
Tihamer Orban - Brookline MA, US
International Classification:
A61K038/28, A61K031/715
US Classification:
514/012000, 514/003000, 514/054000
Abstract:
The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human insulin B-chain or GAD65, and an oil-based carrier approved for human use. Also included are vaccines and kits for the treatment of diabetes mellitus.
Autoantigen Composition
US Patent:
2006018, Aug 17, 2006
Filed:
Apr 13, 2006
Appl. No.:
11/403580
Inventors:
Tihamer Orban - Brookline MA, US
International Classification:
A61K 38/28
US Classification:
514003000
Abstract:
The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human insulin B-chain or GAD65, and an oil-based carrier approved for human use. Also included are vaccines and kits for the treatment of diabetes mellitus.
Diabetes Biomarkers
US Patent:
2013031, Nov 28, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/803581
Inventors:
Tihamer Orban - Brookline MA, US
Assignee:
ORBAN BIOTECH LLC - Brookline MA
International Classification:
G01N 33/50
US Classification:
435 724
Abstract:
A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO-CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO-CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions.